2-18 umer logot Covaxin trials manishe

New Delhi: Tuesday din te phase-2 aro phase-3 clinical trials laga expert panel khan para Bharat Biotech’s COVID-19 vaccine Covaxin toh tui(2) umer para loikena 18 umer khan logot loboli manishe koikena official khobor para janaishe. Etu trial toh alag-alag sites aro AIIMS, Delhi, AIIMS, Patna aro Meditrina Institute of Medical Sciences, Nagpur te 525 subjects te loboli ase koishe. Central Drugs Standard Control Organization (CDSCO) laga COVID-19 Subject Expert Committee (SEC) para Tuesday din te koishe ke, Hyderabad-based Bharat Biotech’s application hesab te phase II/III clinical trials toh safety, reactogenicity aro immunogenicity 2 umer para 18 umer dak te Covaxin jabs trials loboli hotishe. “besi thiri kotha kora beche, committee para phase II/III clinical trial toh 2 umer para 18 umer virion inactivated coronavirus vaccine loboli manishe,” koikena khobor para janaishe. Olop din akhe te SEC meeting February 24 daik te  proposal kora nemite firm logot revised clinical trial protocol toh submit koriboli janaishe. Covaxin toh Bharat Biotech aro Indian Council of Medical Research (ICMR) melaikena bona ase aro etu vaccine toh itya India te COVID-19 vaccination samai umer tangor khan logot kam koris ase koishe.